Is Compounded Semaglutide Legal in 2026?

The Federal Legal Framework for Compounding

To understand why compounded semaglutide's legal status is complicated, you need to understand how federal compounding law works.

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), drug compounding is regulated differently from commercial drug manufacturing. Large-scale compounding — the kind that enabled telehealth companies to offer semaglutide at scale — is primarily permitted under Section 503B of the FD&C Act, which created a category of "outsourcing facilities" that can compound drugs without individual prescriptions under specific conditions.

One of those conditions: the drug being compounded must appear on the FDA's "drug shortage list." The logic is that compounding fills a gap when the FDA-approved product is unavailable. Once the shortage resolves, the rationale for large-scale compounding disappears.

What the February 2025 Shortage List Removal Actually Did

When the FDA removed semaglutide from the drug shortage list in February 2025, it made three things happen simultaneously:

1. Removed the primary legal basis for 503B compounding of semaglutide. 503B facilities that had been legally compounding semaglutide during the shortage suddenly lost their shortage-based authorization.
2. Triggered phase-down deadlines:
   • 503A compounding pharmacies: phase-down by April 22, 2025
   • 503B outsourcing facilities: phase-down by May 22, 2025
3. Initiated the FDA's enforcement authority over pharmacies continuing to compound semaglutide without legal authorization.

Critically, the FDA's shortage list determination itself became contested. Compounding advocates argued that patient access remained insufficient — particularly for patients who couldn't afford brand-name pricing — meaning the shortage effectively continued from a patient access standpoint even if supply existed.

The Court Cases: How Litigation Changed the Picture

Almost immediately after the FDA's shortage list removal and enforcement deadlines were announced, legal challenges were filed:

Outsourcing Facility Association (OFA) Lawsuit

The OFA, representing 503B outsourcing facilities, sued the FDA in federal court challenging the shortage list removal. Their primary arguments:

• The FDA failed to adequately consider patient access when determining the shortage was resolved
• The phase-down timelines were unreasonably short given patient care continuity concerns
• The FDA's process for shortage list determinations lacked sufficient procedural safeguards

Alliance for Pharmacy Compounding (APC) Challenges

503A pharmacies also filed legal challenges, arguing that the FDA's enforcement against traditional compounding pharmacies overstepped regulatory authority.

Court Outcomes

Courts issued mixed rulings across different jurisdictions. Some courts granted temporary restraining orders against FDA enforcement, allowing compounding to continue pending further legal proceedings. Other courts allowed enforcement to proceed. The result was a patchwork of legal outcomes that varied by geography and facility type.

As of 2026, the legal situation remains in flux. Multiple cases are in various stages of appeal. This explains why compounded semaglutide remained available through some channels — particularly through 503B facilities operating in jurisdictions where courts had stayed enforcement.

503A vs. 503B: Why the Distinction Matters

Not all compounding pharmacies are created equal from a regulatory standpoint. The 503A vs. 503B distinction is crucial for patients evaluating whether their provider is legally sound:

503A Traditional Compounding Pharmacies

• Smaller operations regulated primarily by state pharmacy boards
• Can only compound for specific individual patients with prescriptions
• Generally required to phase down semaglutide compounding by April 22, 2025
• Higher legal risk in post-shortage-list environment

503B Outsourcing Facilities

• Larger FDA-registered and inspected facilities
• Can compound for healthcare facilities without individual prescriptions
• Had until May 22, 2025 to phase down under original FDA timeline
• Subject to ongoing litigation that has complicated enforcement
• Relatively stronger legal position due to FDA registration and inspection status

Remedy Meds and the most reputable telehealth providers source exclusively from 503B outsourcing facilities. This provides meaningfully better legal standing than providers using 503A pharmacies.

State-by-State Legal Considerations

While federal law governs the FDA shortage list framework, state pharmacy law adds another dimension. States regulate pharmacy practice within their borders, and state pharmacy boards have varying approaches to compounding:

• Some states have adopted additional restrictions on compounded medications, particularly for medications with commercial equivalents available
• Other states have strong pharmacist practice protections that provide some insulation from federal enforcement
• Most states follow federal framework broadly but have their own inspection and enforcement mechanisms

Telehealth providers that serve patients across state lines must navigate all of these jurisdictions simultaneously. This is another reason why established 503B facilities with dedicated compliance teams have advantages over smaller operations.

What This Means for Patients Practically

Here's the patient-level practical picture:

• Patient legal exposure is minimal. Regulatory enforcement focuses on manufacturers and distributors. Patients receiving compounded semaglutide through valid prescriptions from licensed providers face very low legal risk.
• Provider choice matters. If your provider is sourcing from a non-compliant pharmacy, you may face medication disruptions. Choose providers with 503B pharmacy relationships.
• The situation is still evolving. Legal challenges may result in further changes. What's true today may change within months.
• Have a contingency plan. Know in advance what you'll do if your current provider can no longer supply semaglutide. Transition to tirzepatide or brand-name options can be managed proactively.

Our Recommendation: Remedy Meds

Given the legal complexity, we recommend Remedy Meds for patients seeking compounded semaglutide in 2026. They operate through FDA-registered 503B outsourcing facilities, have remained operational through the regulatory changes, and proactively communicate with patients about any supply changes.

Their 22-minute video consultation with a licensed provider is also more defensible from a prescribing standpoint than purely asynchronous providers — proper medical evaluation matters both for patient safety and regulatory compliance.